Sage Publishing Multimedia logo (light mode)

Multimedia Content from Sage

Webinar

Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing

Presenters

Douglas Flora

Douglas Flora, MD

Executive Medical Director, Oncology Services
St. Elizabeth Healthcare
Edgewood, KY, USA

Douglas Flora, MD

Dr. Doug Flora is a distinguished leader shaping the future of cancer treatment. He serves as the Executive Medical Director of Oncology Services and holds The Robert and Dell Ann Sathe Endowed Chair in Oncology at the Yung Family Cancer Center, St. Elizabeth Healthcare, driving innovation and patient-centered care. A prominent national voice, Dr. Flora is the President-Elect of the Association of Community Cancer Centers (ACCC), where he champions excellence in cancer care delivery nationwide. Furthering his commitment to cutting-edge advancements, he is the founding Editor-in-Chief of the peer-reviewed journal, AI in Precision Oncology, guiding the integration of artificial intelligence into modern oncology practice. Dr. Flora's multifaceted expertise as a clinician, executive, and patient advocate uniquely positions him at the forefront of transforming cancer care through technology and compassionate leadership, ensuring patients benefit from the latest breakthroughs and a holistic approach to treatment.
Midhun Malla

Midhun Malla, MD

Hematologist Oncologist

University of Alabama at Birmingham

Midhun Malla, MD

Dr. Midhun Malla is an associate professor who specializes in the medical treatment of gastrointestinal (GI) malignancies and an active member of Alliance co-operative group committee, currently working on 2 national clinical trial proposals one each in colorectal and hepatocellular carcinomas.

Gastrointestinal (GI) cancer remains one of the deadliest forms of cancer worldwide, with the American Cancer Society predicting about 30,000 new cases and more than 10,000 deaths in the U.S. in 2025. GI cancer relapses remain a major challenge due to small fragments of cancer that persist in the body after a patient has completed treatment. These remnants can evade detection by conventional scans, presenting a persistent risk of cancer recurrence known as molecular residual disease (MRD).

 

In this panel, our industry experts will discuss the impactful role of circulating tumor DNA (ctDNA) testing for MRD assessment in GI cancer management. Key learnings for this webinar:

 

  • The role of MRD testing in risk stratification, refining treatment pathways, and augmenting personalized oncology care
  • Latest evidence supporting MRD as a predictive biomarker in GI malignancies, including its application in the neoadjuvant setting, adjuvant treatment decision-making, early relapse detection, ongoing surveillance, and informing metastatic directed therapy (MDT)
  • How to integrate MRD testing into your practice to enable more precise, personalized, and timely treatment decisions
Natera Signatera